Page last updated: 2024-08-24

atorvastatin and Chronic Hepatitis C

atorvastatin has been researched along with Chronic Hepatitis C in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA	1
Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P	1
Nash, DT	1
Chan, JL; Chung, RT; McMahon, CM; O'Leary, JG	1

Trials

2 trial(s) available for atorvastatin and Chronic Hepatitis C

Article	Year
Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein. Drug research, 2022, Volume: 72, Issue:6 Topics: Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Availability; Cross-Over Studies; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Sofosbuvir	2022
Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:4 Topics: Adult; Aged; Atorvastatin; Female; Hepacivirus; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Virus Replication	2007

Article

Year

Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein.

Drug research, 2022, Volume: 72, Issue:6

Topics: Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Availability; Cross-Over Studies; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Sofosbuvir

2022

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial.

Hepatology (Baltimore, Md.), 2007, Volume: 45, Issue:4

Topics: Adult; Aged; Atorvastatin; Female; Hepacivirus; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Virus Replication

2007

Other Studies

2 other study(ies) available for atorvastatin and Chronic Hepatitis C

Article	Year
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:1 Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged	2016
A statin for a patient with hyperlipidemia and hepatitis C? Postgraduate medicine, 2004, Volume: 115, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors	2004

Article

Year

Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:1

Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged

2016

A statin for a patient with hyperlipidemia and hepatitis C?

Postgraduate medicine, 2004, Volume: 115, Issue:5

Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors

2004